Delek US Holdings to Acquire Remaining Outstanding Shares of Alon USA
Jan 03, 2017 12:31 pm UTC| Business
Combination creates a Permian focused company with refining, logistics, retail and marketing operations with a combined enterprise value of approximately $2.8 billionAll-stock transaction at a fixed exchange ratio of...
Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc
Jan 03, 2017 12:31 pm UTC| Business
DUBLIN, Ireland, Jan. 03, 2017 -- Flamel Technologies SA, completed its previously announced cross-border merger with and into its wholly-owned Irish subsidiary, Avadel Pharmaceuticals plc (NASDAQ:AVDL) (Avadel),...
Flamel Technologies Completes Cross-Border Merger and Becomes Avadel Pharmaceuticals plc
Jan 03, 2017 12:31 pm UTC| Business
DUBLIN, Ireland, Jan. 03, 2017 -- Flamel Technologies SA, completed its previously announced cross-border merger with and into its wholly-owned Irish subsidiary, Avadel Pharmaceuticals plc (NASDAQ:AVDL) (Avadel),...
Otonomy to Present at the J.P. Morgan Healthcare Conference
Jan 03, 2017 12:30 pm UTC| Business
SAN DIEGO, Jan. 03, 2017 -- Otonomy, Inc.(NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that...
Jan 03, 2017 12:30 pm UTC| Business
LOUISVILLE, Ky., Jan. 03, 2017 -- Almost Family, Inc. (Nasdaq:AFAM), a leading provider of home health nursing services, today announced that it has completed its previously announced acquisition of a controlling...
Agios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017
Jan 03, 2017 12:30 pm UTC| Business
CAMBRIDGE, Mass., Jan. 03, 2017 -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the company is scheduled to present at the...
Dermira Initiates Phase 3 Clinical Program in Acne
Jan 03, 2017 12:30 pm UTC| Business
First patients dosed in Phase 3 program evaluating olumacostat glasaretil, a novel topical molecule, in patients with acne vulgarisTwo Phase 3 trials expected to enroll a total of 1,400 patientsTopline results expected in...